avapritinib,nivolumab,regorafenib
blueprint medicines,bms,bayer
['regorafenib', 'avapritinib', 'detection']
dr. serrano reports on ctdna in voyager ph3 trial in tx of advanced gist avapritinib vs regorafenib. high rate of mutation detection (86%). prognostic role for ctdna. detection of atpbp mut in kit correlated with reduced activity of avap but not rego #asco22
Medical oncologist - Developmental Therapeutics - NIH/NCI - opinions my own - retweet ? endorsement